1. SOCS, inflammation, and cancer
- Author
-
Minako Ito, Taisuke Kondo, Akihiko Yoshimura, and Kyoko Inagaki-Ohara
- Subjects
business.industry ,Suppressor of cytokine signaling 1 ,medicine.medical_treatment ,STAT ,Cancer ,therapeutic target ,General Medicine ,Review ,medicine.disease ,Suppressor of cytokine signalling ,SOCS ,Cytokine ,Hormone receptor ,inflammation ,Immunology ,Cancer research ,Medicine ,cancer ,SOCS3 ,Signal transduction ,Receptor ,business - Abstract
Signal transduction pathways elicited by cytokines and hormones have been shown to regulate distinct stages of development. Suppressor of cytokine signaling (SOCS) proteins are negative feedback regulators of cytokine signaling mediated by the JAK-STAT signaling pathway. In particular, SOCS1 and SOCS3 are potent inhibitors of JAKs and can play pivotal roles in inflammation, as well as in the development and progression of cancers. Abnormal expression of SOCS1 and SOCS3 in cancer cells has been reported in human carcinoma associated with dysregulation of signals from cytokine receptors, Toll-like receptors (TLRs), and hormone receptors, resulting in malignancies. In this review, we focus on the role of SOCS1 and SOCS3 in cancer development. In addition, the potential of SOCS as a therapeutic target and diagnostic aid will be discussed.
- Published
- 2013